Physicians' Academy for Cardiovascular Education

Anticoagulation

Results with novel FXI inhibitor in AF set the stage for phase 3 trials

3' education - Nov. 16, 2023 - Christian Ruff, MD

Lower stroke risk with DOAC vs. aspirin in subclinical atrial fibrillation

3' education - Nov. 12, 2023 - Jeff Healey, MD

International survey of secondary prevention of CHD

5' education - Oct. 11, 2023 - John W. McEvoy, MD, PhD, and Joris Holtrop, MD

What is the best antithrombotic treatment post-PCI?

3' education - Sep. 21, 2023 - Marco Valgimigli, MD, PhD

Unexpected results after switching from VKA to DOAC in frail older patients with AF

3' education - Aug. 28, 2023 - Linda Joosten, MD

No signal for efficacy of DOAC in patients with atrial high-rate episodes

3' education - Aug. 25, 2023 - Paulus Kirchhof, MD

Unexpected findings when comparing DOAC with VKA in rheumatic AF

3' education - Sep. 15, 2022 - Prof. Ganesan Karthikeyan, MD

FXIa inhibition in non-cardioembolic stroke patients

3' education - Aug. 29, 2022 - Ashkan Shoamanesh, MD

Management of cancer-associated VTE

10' education - May 12, 2022 - Prof. Stavros Konstantinides, MD

Optimizing oral anticoagulation management for patients with AF

10' education - May 3, 2022 - Prof. Robert Storey, MD

A positive view on a negative trial with DOAC after TAVR

3' education - Apr. 19, 2022 - Megan Coylewright, MD

Atrial fibrillation: From risk prediction to clinical outcomes

10' education - Apr. 6, 2022 - Prof. Stefan Hohnloser, MD

Low-dose NOAC after COVID-19 hospitalization in patients with high thrombotic risk

3' education - Jan. 11, 2022 - Prof. Freek Verheugt, MD, PhD

Therapeutic dose of heparin in COVID-19 - the jury is still out

5' education - Oct. 26, 2021 - Prof. Hugo ten Cate, MD, PhD

NOAC as possible treatment option in patients with AF after successful TAVI

5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD

No superiority with NOAC compared to standard care following TAVI

5' education - May 17, 2021 - Jean-Philippe Collet, MD, PhD

Clinical outcomes with low dose vs. high dose DOAC in AF

5' education - Mar. 30, 2021 - Prof. Jan Steffel, MD

No decrease in thrombotic complications in second COVID-19 wave

5' education - Feb. 4, 2021 - Fleur Kaptein, MD

Updates in the 2020 AF guidelines

3' education - Sep. 2, 2020 - Prof. Isabelle van Gelder, MD

Triage strategy for outpatient management of PE patients based on HESTIA non-inferior to sPESI

5' education - Aug. 31, 2020 - Prof. Menno Huisman, MD

COVID-19 associated thrombotic complications

5' education - Apr. 22, 2020 - Erik Klok, MD, PhD

Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI

3' education - Mar. 30, 2020 - Dr. Jur ten Berg, MD, PhD - ACC 2020

NOAC plus aspirin superior to aspirin alone for preventing major adverse limb and CV events

3' education - Mar. 29, 2020 - Dr. Marc P. Bonaca, MD - ACC 2020

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

NOAC non-inferior to heparin in reducing cancer-associated VTE recurrence

10' education - Mar. 29, 2020 - Prof. Menno Huisman - ACC 2020

Challenges in prescribing DOACs for stroke prevention in AF

5' education - Mar. 2, 2020 - Prof. Freek Verheugt and John Eikelboom

A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial

3' education - Nov. 25, 2019 - Prof. Freek Verheugt - AHA 2019, Philadelphia

Estimating individual lifetime benefit and bleeding risk with NOAC addition to asprin in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Tamar de Vries, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Clear results with NOAC monotherapy in patients with CAD and AF

3' education - Sep. 2, 2019 - Prof. Freek Verheugt

Results with novel FXI inhibitor in AF set the stage for phase 3 trials

3' education - Nov. 16, 2023 - Christian Ruff, MD
To the suprise of the investigators of the AZALEA-TIMI 71 trial, the Data Safety Monitoring Committe recommended early termination of the phase 2 trial with the FXI inhibitor abelacimab in patients with AF. What are the findings of an interim analysis?

AHA 2023 To the suprise of the investigators of the AZALEA-TIMI 71 trial, the Data Safety Monitoring Committe recommended early termination of the phase 2 trial with the FXI inhibitor abelacimab in patients with AF. What are the findings of an interim analysis?

Lower stroke risk with DOAC vs. aspirin in subclinical atrial fibrillation

3' education - Nov. 12, 2023 - Jeff Healey, MD
**AHA 2023** In the ARTESIA trial, patients with subclinical AF were randomized to apixaban or aspirin and followed for stroke or systemic embolism and major bleeding. Jeff Healey discusses the results.

AHA 2023 In the ARTESIA trial, patients with subclinical AF were randomized to apixaban or aspirin and followed for stroke or systemic embolism and major bleeding. Jeff Healey discusses the results.

DOAC reduces stroke in patients with subclinical atrial fibrillation

News - Nov. 12, 2023

AHA 2023 Apixaban reduced stroke or systemic embolism in patients with subclinical atrial fibrillation compared with aspirin in the ARTESIA trial. Apixaban increased the risk of major bleeding but there was no increase intracranial bleeding or fatal bleeding.

Factor XI inhibitor reduces major or clinically relevant non-major bleeding in AF patients

News - Nov. 12, 2023

AHA 2023 What are the findings of a phase 2 trial in which two doses of the FXI/XIa inhibitor abelacimab were compared with rivaroxaban with regard to the safety outcome of bleeding in patients with AF?

International survey of secondary prevention of CHD

5' education - Oct. 11, 2023 - John W. McEvoy, MD, PhD, and Joris Holtrop, MD
**ESC Congress 2023** The results of the INTERASPIRE survey call for action to improve secondary prevention of CHD globally. Joris Holtrop interviews John McEvoy about the study results.

ESC Congress 2023 The results of the INTERASPIRE survey call for action to improve secondary prevention of CHD globally. Joris Holtrop interviews John McEvoy about the study results.

What is the best antithrombotic treatment post-PCI?

3' education - Sep. 21, 2023 - Marco Valgimigli, MD, PhD
**ESC Congress 2023** Marco Valgimigli gives his view on the results of the STOPDAPT-3 study and discusses the added value of the insights from this study in the optimization of antithrombotic therapy post-PCI.

ESC Congress 2023 Marco Valgimigli gives his view on the results of the STOPDAPT-3 study and discusses the added value of the insights from this study in the optimization of antithrombotic therapy post-PCI.

Phase 2 study with FXI inhibitor in AF stopped early due to overwhelming efficacy

News - Sep. 19, 2023

The AZALEA-TIMI 71 trial, in which the efficacy of the factor XI/XIa inhibitor abelacimab was compared with rivaroxaban in patients with AF at moderate-to-high risk of stroke, has been stopped early due to an overwhelming reduction in bleeding.

Consistent treatment effect of DOAC regardless of valvular heart disease etiology and event risk

News - Sep. 5, 2023

ESC Congress 2023 An analysis of the RIVER trial showed that among patients with atrial fibrillation or flutter and a bioprosthetic mitral valve, patients with rheumatic heart disease did not have an increased risk of thrombotic and bleeding events.

Isolated distal DVT in cancer calls for longer DOAC treatment

News - Aug. 29, 2023

ESC Congress 2023 In cancer patients with isolated distal deep vein thrombosis (DVT), 12 months of edoxaban treatment was superior to 3 months in lowering thrombotic risk, without increasing bleeding risk.

Unexpected results after switching from VKA to DOAC in frail older patients with AF

3' education - Aug. 28, 2023 - Linda Joosten, MD
**ESC Congress 2023** In the FRAIL-AF trial, frail older adults with AF were randomized to switch from a VKA to a DOAC or to continue using a VKA. Linda Joosten talks about the unexpected results of this trial.

ESC Congress 2023 In the FRAIL-AF trial, frail older adults with AF were randomized to switch from a VKA to a DOAC or to continue using a VKA. Linda Joosten talks about the unexpected results of this trial.

Switching to DOAC associated with higher risk of bleeding in frail patients with AF

News - Aug. 28, 2023

ESC Congress 2023 The FRAIL-AF trial showed that frail older patients with AF who switched from VKA to a DOAC had a 69% higher risk of bleeding, compared with patients who continued using VKA. There was no difference between DOACs and VKA in stroke reduction in this patient population.

DOAC does not prevent stroke in patients with atrial high-rate episodes

News - Aug. 25, 2023

ESC Congress 2023 Atrial high-rate episodes resemble atrial fibrillation and clinicians may prescribe oral anticoagulation for these patients, but evidence of effectiveness is lacking. Therefore, the NOAF-AFNET 6 trial was performed.